Skip to search formSkip to main contentSkip to account menu

[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study.

Patients undergoing PET-CT with [18F]FDG and [18F]FCH-PET-CTs should not be systematically performed for staging a first diagnosis of hepatocellular carcinoma, as they modified treatment decisions only in a minority of patients.
PubMed (opens in a new tab)

WED-084 Added-value of PET imaging to AFP score in predicting HCC recurrence after liver transplantation

Publisher (opens in a new tab)

OS-077 Added value of a combination of positron emission tomography with 18F-FDG and 18 F-Fluorocholine for staging optimization and treatment modification in patients with hepatocellular carcinoma:…

Publisher (opens in a new tab)

IC‐02‐02: THE USE OF NEUROIMAGING BIOMARKERS IN PRECLINICAL ALZHEIMER'S DISEASE

This work presents a meta-analysis of 120 patients with Alzheimer’s disease over a 12-month period and shows clear trends in prognosis, disease progression, and prognosis in women and men with dementia.
Wiley (opens in a new tab)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)